Halstead Michael — SEC insider filings
SEC reporting owner CIK 1521548. 30 insider filings on record with FilingPulse; latest filed 2026-09-21.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2020-11-19 to 2026-09-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 100,000 shares, $1,347,050 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 50 legs across 18 filings — 616,833 shares, $31,055,921 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 77.
- Largest priced transaction: sale of 104,775 shares @ $47.84 ($5,012,436) in Intra-Cellular Therapies, Inc., filed 2021-12-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intra-Cellular Therapies, Inc. (ITCI) | President | 28 | — | 50 legs · 616,833 sh · $31,055,921 | 77 |
| CYBIN INC. (CYBN) | Chief Executive Officer | 2 | 1 leg · 100,000 sh · $1,347,050 | — | — |
Insider filings — Halstead Michael
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 4 | CYBIN INC. (CYBN) | Purchase (P): 100,000 @ $13.47 | EDGAR |
| 2026-09-17 | 3 | CYBIN INC. (CYBN) | Holdings only — no transactions reported | EDGAR |
| 2025-04-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Disposition to issuer (D): 21,307 @ $132 · Disposition to issuer (D): 40,472 (derivative) · Disposition to issuer (D): 17,916 (derivative) · Disposition to issuer (D): 13,133 (derivative) · Disposition to issuer (D): 24,478 (derivative) · Disposition to issuer (D): 45,454 (derivative) · +4 more | EDGAR |
| 2025-03-10 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 13,133 · Tax withholding (F): 6,718 @ $131.19 · Option exercise (M): 7,345 · Tax withholding (F): 3,757 @ $131.24 · Option exercise (M): 13,133 (derivative) @ $0 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 12,239 · Tax withholding (F): 6,261 @ $128.20 · Option exercise (M): 12,239 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 11,017 @ $0 · Tax withholding (F): 5,691 @ $127 · Grant/award (A): 45,454 (derivative) @ $0 | EDGAR |
| 2024-11-14 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 22,869 @ $23.94 · Sale (S): 15,105 @ $88.72 · Sale (S): 6,116 @ $89.63 · Sale (S): 1,648 @ $90.89 · Option exercise (M): 18,714 @ $36.89 · Sale (S): 13,371 @ $88.17 · +3 more | EDGAR |
| 2024-03-11 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Sale (S): 12,912 @ $66.14 · Sale (S): 220 @ $66.81 · Option exercise (M): 7,345 · Sale (S): 6,107 @ $65.82 · Sale (S): 1,238 @ $66.70 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 13,132 · Option exercise (M): 13,132 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 36,717 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 7,907 · Sale (S): 300 @ $68.54 · Sale (S): 7,215 @ $69.54 · Sale (S): 392 @ $70.13 · Option exercise (M): 7,907 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 11,860 @ $0 · Sale (S): 11,146 @ $66.37 · Sale (S): 714 @ $67.17 | EDGAR |
| 2024-01-12 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 46,115 @ $12.73 · Option exercise (M): 3,885 @ $23.94 · Sale (S): 18,154 @ $66.31 · Sale (S): 30,360 @ $67.10 · Sale (S): 1,486 @ $67.80 · Option exercise (M): 46,115 (derivative) @ $0 · +1 more | EDGAR |
| 2023-11-14 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 15,164 @ $15.47 · Option exercise (M): 34,836 @ $12.73 · Sale (S): 8,933 @ $53.37 · Sale (S): 41,067 @ $54.01 · Option exercise (M): 15,164 (derivative) @ $0 · Option exercise (M): 34,836 (derivative) @ $0 | EDGAR |
| 2023-07-07 | 4/A | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 40,472 (derivative) @ $0 | EDGAR |
| 2023-03-13 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 16,708 @ $0 · Sale (S): 14,208 @ $43.20 · Sale (S): 2,500 @ $42.52 · Option exercise (M): 7,344 · Sale (S): 6,868 @ $44.99 · Sale (S): 476 @ $44.15 · +1 more | EDGAR |
| 2023-03-08 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 39,398 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 7,906 · Sale (S): 7,906 @ $47.03 · Option exercise (M): 7,906 (derivative) @ $0 | EDGAR |
| 2023-02-22 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 11,139 · Sale (S): 9,296 @ $46.56 · Sale (S): 643 @ $47.23 · Sale (S): 1,100 @ $48.68 · Sale (S): 100 @ $49.60 · Option exercise (M): 11,139 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 50,000 @ $15.47 · Sale (S): 27,204 @ $53.94 · Sale (S): 22,796 @ $53.48 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 17,916 (derivative) @ $0 · Grant/award (A): 22,034 (derivative) @ $0 | EDGAR |
| 2022-02-25 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 7,906 · Sale (S): 3,718 @ $52.38 · Sale (S): 4,188 @ $51.62 · Option exercise (M): 7,906 (derivative) @ $0 | EDGAR |
| 2022-02-23 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 11,139 · Sale (S): 6,589 @ $55.69 · Sale (S): 4,550 @ $54.98 · Option exercise (M): 11,139 (derivative) @ $0 | EDGAR |
| 2022-01-11 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 19,639 · Sale (S): 2,504 @ $41.74 · Sale (S): 12,755 @ $40.81 · Sale (S): 4,380 @ $40.12 · Option exercise (M): 19,639 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 25,000 @ $13.86 · Option exercise (M): 88,146 @ $17.57 · Option exercise (M): 63,717 @ $15.73 · Sale (S): 22,620 @ $48.62 · Sale (S): 104,775 @ $47.84 · Sale (S): 36,434 @ $46.87 · +5 more | EDGAR |
| 2021-02-25 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 18,714 (derivative) @ $0 · Grant/award (A): 23,719 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 11,139 · Sale (S): 10,039 @ $39.28 · Sale (S): 1,100 @ $38.91 · Option exercise (M): 11,139 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 19,638 · Sale (S): 17,702 @ $32.07 · Sale (S): 1,936 @ $31.65 · Option exercise (M): 19,638 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 16,160 · Sale (S): 12,986 @ $31.39 · Sale (S): 3,174 @ $30.94 · Option exercise (M): 16,160 (derivative) @ $0 | EDGAR |
| 2020-11-19 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 75,000 @ $13.86 · Sale (S): 75,664 @ $27.60 · Sale (S): 3,761 @ $27.95 · Option exercise (M): 75,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1521548 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs